Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2017 | 1 |
2024 | 2 |
Search Results
3 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.
Invest New Drugs. 2017 Aug;35(4):471-477. doi: 10.1007/s10637-017-0427-2. Epub 2017 Jan 20.
Invest New Drugs. 2017.
PMID: 28105566
Clinical Trial.
Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction Study.
Moreno I, Hernández T, Calvo E, Fudio S, Kahatt C, Fernández C, Iglesias JL, Corral G, Pérez-Ramos L, Montilla L, Zeaiter A, Lubomirov R.
Moreno I, et al. Among authors: iglesias jl.
Pharmaceuticals (Basel). 2024 Jan 30;17(2):182. doi: 10.3390/ph17020182.
Pharmaceuticals (Basel). 2024.
PMID: 38399397
Free PMC article.
Item in Clipboard
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study.
Moreno I, Hernández T, Calvo E, Fudio S, Kahatt C, Martínez S, Iglesias JL, Calafati RO, Pérez-Ramos L, Montilla L, Zeaiter A, Lubomirov R.
Moreno I, et al. Among authors: iglesias jl.
Mar Drugs. 2024 Apr 16;22(4):178. doi: 10.3390/md22040178.
Mar Drugs. 2024.
PMID: 38667795
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite